

GLASS guide for hospital AMC surveillance


Feedback from countries -

GLASS AMC Team

GLASS guide for hospital AMC* surveillance (2020)



- Aims to assist countries to establish national mechanisms for routine AMC monitoring in hospitals
- Considers variable levels of capacity of countries
- Describes:
 - methodology for collecting and analysing AMC data at hospital level
 - choice of data sources
 - hospital activity metrics (denominators)
 - surveillance framework re: hospital sectors and organisational levels for monitoring



https://apps.who.int/iris/bitstream/handle/10665/336182/9789240000421-eng.pdf

^{*} AMC = aggregated sales data (info on qty & type of antimicrobials)

42 countries responded on the online questionnaire between October 2020 and February 2021



Africa	4 (9.5%)
Americas	4 (9.5%)
Eastern Mediterranean	14 (33.3%)
Europe	12 (28.6%)
South-East Asia	3 (7.1%)
Western Pacific	5 (11.9%)

Low & lower-middle income **13** (31.0%)

Upper-middle income **9** (21.4%)

High income **20** (47.6%)

GLASS countries **35** (83.3%)

Non-GLASS countries 7 (16.7%)


Preliminary feedback report


Countries can still respond until the end of April



Q1: Is the methodology presented in a clear manner in the GLASS guide for hospital AMC surveillance?








No


2 countries: Clear presentation, but:

- Complex description of hospital denominators
- Unclear terminology re: units of medicines
- Avoid concrete targets for AWaRe categories

Q2: Does the GLASS guide for hospital AMC surveillance provide practical tools for surveillance of AMC in hospitals?







No/ DK


Need for clarification/additional tools:


- Manuals & template for data input
- Stepwise approach when resources are limited
- Guidance and examples on how to use AMC data to inform local treatment guidelines

Q3: Is the GLASS guide for hospital AMC surveillance useful for enhancing AMC surveillance in your country?

No









- Already doing AMC surveillance at hospitals, but data analysis is done centrally due to errors
- Not sure about applicability as hospitals may vary or use different IT systems

Q4: Are hospital pharmacists in your country knowledgeable on ATC/DDD system to undertake AMC monitoring in facilities?

No








- HIC: Errors are made at hospital level
- LMIC: ATC/DDD system not part of curriculum
- LMIC: No training in drug utilization research, pharmacoepidemiology, clinical pharmacy


WHO: ATC/DDD is prerequisite for AMC surveillance (priority support area)

Q5: Is it possible to separate procurement / dispensing records for inpatients and outpatients at hospital level in your country?

No







- To differentiate inpatients from outpatients, need to change infrastructure, IT, recording procedures
- Private hospitals are not willing to share records

WHO: Problem to calculate & analyse data


Q6: Are antimicrobials for inpatients dispensed at wards (not purchased from the hospital pharmacy) in your country?

80

■ No (%) ■ Don't know (%)

100





Q7: If purchase of antimicrobials for inpatients outside hospitals is common in your country, estimate % those antimicrobials.



- Answer provided by 8 countries only
- Wide range of % of antimicrobials (self)purchased outside hospitals
 - < 5% in 2 countries (HIC and UMIC)
 - **10-20%** in 1 MIC
 - **50-80%** in 1 MIC and 3 LIC
 - 99% in 1 LIC in conflict zone

YES

• 5/13 of LIC & low MIC have high % of antimicrobials purchased outside hospital

WHO: Need info on self-purchase of antimicrobials from more countries


Need surveys to estimate shortages and % self-purchased antimicrobials

Q8: Would you consider setting up such a surveillance program in your country with the help of WHO according to this guide?



80

100



Q9: Please share any additional comments you may have on GLASS guide for hospital AMC surveillance.



Type of support needed to implement the GLASS Guide

- Technical support (training workshops on AMC methodology, data collection and analysis)
- Financial support for LIC (computers, printers, stationary)
- Logistics, transport
- Additional tools (software tools, information systems, electronic records, tools for DDD calculations, educational materials)
- Support on use of AMC data (link to AWaRE, treatment guidelines, antimicrobial stewardship)

General remarks

- Linkage to other surveillance systems, including AMR
- Support on the implementation on NAPs on AMR and awareness raising on AMR

